Newsblaster Archived Run Click here to return to today's news. Monday, June 2, 2008 Articles from 05/30/2008 to 06/02/2008 Last update: 3:32 AM EST
Search for: Offline summarization (match summaries) Hybrid summarization Online summarization Offline summarization (match articles) U.S. World Finance Sci/Tech Entertainment Sports View Today's Images Back to Archive Index About Newsblaster About today's run Newsblaster in Press Academic Papers Article Sources: washingtonpost.com (110 articles) boston.com (82 articles) news.bbc.co.uk (72 articles) seattletimes. nwsource.com (62 articles) nypost.com (47 articles) latimes.com (44 articles) abcnews.go.com (40 articles) baltimoresun.com (35 articles) sfgate.com (31 articles) dallasnews.com (27 articles) cbc.ca (24 articles) suntimes.com (21 articles) timesonline.co.uk (20 articles) foxnews.com (18 articles) cnn.com (15 articles) haaretz.com (14 articles) ft.com (13 articles) msnbc.msn.com (5 articles) women. timesonline.co.uk (4 articles) cbsnews.com (3 articles) sportsillustrated. cnn.com (2 articles) weblogs. baltimoresun.com (2 articles) money.cnn.com (1 article) lakersblog. latimes.com (1 article)	Erbitux Works Well for Two-Thirds of Colon Cancer Patients Summary from multiple countries, from articles in English p (06-01) 04:00 PDT Chicago A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left doctors excited about a possible new way to fight the disease. (article 6) Some two-thirds of colon cancer patients have the normal, or "wild-type" form of the gene, according to the new study. (article 3) A six-month study of 212 current or heavy smokers found a reduction in a specific type of precancerous change in lung cells in people who took a high dose of Celebrex compared with those who took a placebo. (article 8) A major study, released today, found that a drug commonly known to treat brittle bones also showed promise in dealing with early-stage breast cancer and could change the way many breast cancer patients are treated. (article 4) After five years, researchers found that the hormone therapy, when used with Zometa, reduced the risk of breast cancer recurrence by 35 percent compared to patients who received hormone therapy alone. (article 4) The Austrian researchers also found that women who took Zometa (zoledronic acid) had a 30 percent lower risk of the cancer spreading to the bone, with other benefits as well. (article 5) Other summaries about this story: Summary from the United Kingdom, from articles in English (1 articles) [compare] Summary from United States, from articles in English (9 articles) [compare] Event tracking: Track this story's development in time Story keywords cancer, Lung, patients, breast, Erbitux Source articles Study is seen as boost for ImClone (boston.com, 06/02/2008, 718 words) Erbitux Plus Chemo Improves Lung Cancer Outcomes (Washington Post, 05/31/2008, 496 words) Erbitux Works Well for Two-Thirds of Colon Cancer Patients (Washington Post, 06/01/2008, 618 words) ABC News: Bone Drug Offers Hope on Breast Cancer (ABCNews, 05/31/2008, 334 words) Bone Drug Lowers Risk of Breast Cancer Recurrence (Washington Post, 05/31/2008, 586 words) Zometa seen cutting return of disease and preventing bone loss (sfgate.com, 06/01/2008, 633 words) Women face increased cancer risk (BBC News, 05/30/2008, 336 words) Celebrex shows promise in lung cancer prevention (Washington Post, 06/01/2008, 315 words) Celebrex May Reduce Levels of Lung Cancer Biomarker (Washington Post, 06/01/2008, 422 words) Lung cancer patients fight stigma (msnbc.msn.com, 05/30/2008, 649 words) blaster@cs.columbia.edu